分子標的治療の副作用対策: Everolimus

• 三神, 一哉

  京都府立医科大学大学院医学研究科泌尿器外科学

• 本郷, 文弥

  京都府立医科大学大学院医学研究科泌尿器外科学

• 三木, 恒治

  京都府立医科大学大学院医学研究科泌尿器外科学

書誌事項

タイトル別名

• Management of Side Effects of Everolimus Treatment for Metastatic Renal Cell Carcinoma
• ブンシ ヒョウテキ チリョウ ノ フクサヨウ タイサク : Everolimus

抄録

Treatment with everolimus is known to prolong progression-free survival in patients with renal cell carcinoma resistant against tyrosine-kinase inhibitor therapy. The side effects must be known for more effective use of this drug. Information of side effects was collected from a randomized controlled study, the early post-marketing phase vigilance and from our own experience. Interstitial lung disease (ILD) was a potentially severe side effect. Incidence of ILD was relatively large compared with that of other target therapy agents. Infections, thrombocytopenia, stomatitis and others were experienced as other side effects. However, there were few uncontrollable side effects. Management of side effects of everolimus can be improved by obtaining sufficient knowledge.

収録刊行物

• 泌尿器科紀要

  泌尿器科紀要 58 (11), 647-650, 2012-11

  泌尿器科紀要刊行会

キーワード

• Metastatic RCC
• Everolimus
• Side effects
• ILD

詳細情報

• CRID: 1050564285706683776
• NII論文ID: 120005054811
• NII書誌ID: AN00208315
• ISSN: 00181994
• HANDLE: 2433/166341
• NDL書誌ID: 024105698
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I024105698
• Web Site: https://search.jamas.or.jp/link/ui/2013175498
• 本文言語コード: ja
• 資料種別: departmental bulletin paper
• データソース種別:
  • IRDB
  • NDL
  • CiNii Articles